Treatment options for Stage III-N2 Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Cohort Study
Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare and distinct subset of non-small cell lung cancer (NSCLC), accounting for a mere 0.9% of all lung malignancies. Its occurrence is intimately linked to Epstein-Barr virus (EBV) infection and is more prevalent in specific regions such as Guangdong Province, Hong Kong, Taiwan, and Singapore [1 –2]. In 2021, the classification of thoracic tumors by World Health Organization recognized PLELC as a variant of squamous cell carcinoma [3]. Nevertheless, PLELC exhibits noteworthy atypical characteristics within the NSCLC category.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Zan Hou, Ying Guo, Xiujiao Shen, Baiqiang Dong, Mingchun Li, Mingdian Wang, Qiong Li, Shining Li, Runzhe Chen, Ming chen Source Type: research